Trial Profile
An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Oct 2019
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Expanded access
- Sponsors Novartis Pharma
- 24 Sep 2019 Results assessing safety and tolerability of imatinib in patients with GIST in an adjuvant setting published in the Oncology Research and Treatment
- 08 Aug 2011 New trial record